Gene therapy with beta-defensin 2 induces antitumor immunity and enhances local antitumor effects

Human Gene Therapy

Volumn 25, Issue 1, 2014, Pages 63-72

  Li, Dan ^a   Wang, Wei ^a   Shi, Hua Shan ^a   Fu, Yi Jie ^a   Chen, Xiang ^a   Chen, Xian Cheng ^a   Liu, Yan Tong ^a   Kan, Bing ^a   Wang, Yong Sheng ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA DEFENSIN 2;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; RECOMBINANT PLASMID; SPLEEN CELL; TUMOR IMMUNITY;

ANIMALS; BETA-DEFENSINS; CELL LINE, TUMOR; CHEMOTACTIC FACTORS; CHEMOTAXIS; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; GENETIC THERAPY; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, KNOCKOUT; NEOPLASMS; PLASMIDS; TRANSFECTION;

EID: 84891781300     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2013.161     Document Type: Article

References (54)

1. Aarbiou, J., Tjabringa, G. S., Verhoosel, R. M., et al. (2006). Mechanisms of cell death induced by the neutrophil antimicrobial peptides alpha-defensins and LL-37. Inflamm. Res. 55, 119-127.
2. Andreani, V., Gatti, G., Simonella, L., et al. (2007). Activation of Toll-like receptor 4 on tumor cells in vitro inhibits subsequent tumor growth in vivo. Cancer Res. 67, 10519-10527.
3. Appay, V., Jandus, C., Voelter, V., et al. (2006). New generation vaccine induces effective melanoma-specific CD8 + T cells in the circulation but not in the tumor site. J. Immunol. 177, 1670-1678.
4. Banchereau, J., and Steinman, R. M. (1998). Dendritic cells and the control of immunity. Nature 392, 245-252.
5. Banchereau, J., Briere, F., Caux, C., et al. (2000). Immunobiology of dendritic cells. Annu. Rev. Immunol. 18, 767-811.
6. Biragyn, A., Tani, K., Grimm, M. C., et al. (1999). Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat. Biotechnol. 17, 253-258.
7. Biragyn, A., Surenhu, M., Yang, D., et al. (2001). Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J. Immunol. 167, 6644-6653.
8. Biragyn, A., Ruffini, P. A., Leifer, C. A., et al. (2002). Toll-like receptor 4-dependent activation of dendritic cells by betadefensin 2. Science 298, 1025-1029.
9. Biragyn, A., Schiavo, R., Olkhanud, P., et al. (2007). Tumorassociated embryonic antigen-expressing vaccines that target CCR6 elicit potent CD8+ T cell-mediated protective and therapeutic antitumor immunity. J. Immunol. 179, 1381-1388.
10. Blanco, P., Palucka, A. K., Gill, M., et al. (2001). Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 294, 1540-1543.
11. Bonnotte, B., Crittenden, M., Larmonier, N., et al. (2004). MIP-3alpha transfection into a rodent tumor cell line increases intratumoral dendritic cell infiltration but enhances (facilitates) tumor growth and decreases immunogenicity. J. Immunol. 173, 4929-4935.
12. Caux, C., Ait-Yahia, S., Chemin, K., et al. (2000). Dendritic cell biology and regulation of dendritic cell trafficking by chemokines. Springer Semin. Immunopathol. 22, 345-369.
13. Chen, Z., Moyana, T., Saxena, A., et al. (2001). Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int. J. Cancer 93, 539-548.
14. Chiodoni, C., Paglia, P., Stoppacciaro, A., et al. (1999). Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response. J. Exp. Med. 190, 125-133.
15. Conejo-Garcia, J. R., Benencia, F., Courreges, M. C., et al. (2004). Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat. Med. 10, 950-958.
16. Dhodapkar, M. V., Steinman, R. M., Krasovsky, J., et al. (2001). Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. 193, 233-238.
17. Eguchi, J., Kuwashima, N., Hatano, M., et al. (2005). IL-4-transfected tumor cell vaccines activate tumor-infiltrating dendritic cells and promote type-1 immunity. J. Immunol. 174, 7194-7201.
18. Fioretti, F., Fradelizi, D., Stoppacciaro, A., et al. (1998). Reduced tumorigenicity and augmented leukocyte infiltration after monocyte chemotactic protein-3 (MCP-3) gene transfer: perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumor. J. Immunol. 161, 342-346.
19. Fong, L., and Engleman, E. G. (2000). Dendritic cells in cancer immunotherapy. Annu. Rev. Immunol. 18, 245-273.
20. Furumoto, K., Soares, L., Engleman, E. G., and Merad, M. (2004). Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J. Clin. Invest. 113, 774-783.
21. Fushimi, T., Kojima, A., Moore, M. A., and Crystal, R. G. (2000). Macrophage inflammatory protein 3alpha transgene attracts dendritic cells to established murine tumors and suppresses tumor growth. J. Clin. Invest. 105, 1383-1393.
22. Gabrilovich, D. (2004). Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 4, 941-952.
23. Gatti, G., Rivero, V., Motrich, R. D., and Maccioni, M. (2006). Prostate epithelial cells can act as early sensors of infection by up-regulating TLR4 expression and proinflammatory mediators upon LPS stimulation. J. Leukoc. Biol. 79, 989-998.
24. Gera, J. F., and Lichtenstein, A. (1991). Human neutrophil peptide defensins induce single strand DNA breaks in target cells. Cell Immunol. 138, 108-120.
25. Grigat, J., Soruri, A., Forssmann, U., et al. (2007). Chemoattraction of macrophages, T lymphocytes, and mast cells is evolutionarily conserved within the human alpha-defensin family. J. Immunol. 179, 3958-3965.
26. Hirao, M., Onai, N., Hiroishi, K., et al. (2000). CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res. 60, 2209-2217.
27. Howard, O. M., Dong, H. F., Su, S. B., et al. (2005). Autoantigens signal through chemokine receptors: uveitis antigens induce CXCR3-and CXCR5-expressing lymphocytes and immature dendritic cells to migrate. Blood 105, 4207-4214.
28. Hubert, P., Herman, L., Maillard, C., et al. (2007). Defensins induce the recruitment of dendritic cells in cervical human papillomavirus-associated (pre)neoplastic lesions formed in vitro and transplanted in vivo. FASEB J. 21, 2765-2775.
29. Kaiser, A., Bercovici, N., Abastado, J. P., and Nardin, A. (2003). Naive CD8 + T cell recruitment and proliferation are dependent on stage of dendritic cell maturation. Eur. J. Immunol. 33, 162-171.
30. Kanzler, H., Barrat, F. J., Hessel, E. M., and Coffman, R. L. (2007). Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med. 13, 552-559.
31. Khazanov, E., Simberg, D., and Barenholz, Y. (2006). Lipoplexes prepared from cationic liposomes and mammalian DNA induce CpG-independent, direct cytotoxic effects in cell cultures and in mice. J. Gene Med. 8, 998-1007.
32. Kirk, C. J., Hartigan-O'Connor, D., Nickoloff, B. J., et al. (2001). T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cellbased immunotherapy. Cancer Res. 61, 2062-2070.
33. Lapteva, N., Seethammagari, M. R., Hanks, B. A., et al. (2007). Enhanced activation of human dendritic cells by inducible CD40 and Toll-like receptor-4 ligation. Cancer Res. 67, 10528-10537.
34. Lapteva, N., Aldrich, M., Rollins, L., et al. (2009). Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity. Mol. Ther. 17, 1626-1636.
35. Lichtenstein, A. (1991). Mechanism of mammalian cell lysis mediated by peptide defensins. Evidence for an initial alteration of the plasma membrane. J. Clin. Invest. 88, 93-100.
36. Lichtenstein, A., Ganz, T., Selsted, M. E., and Lehrer, R. I. (1986). In vitro tumor cell cytolysis mediated by peptide defensins of human and rabbit granulocytes. Blood 68, 1407-1410.
37. Ma, X. T., Xu, B., An, L. L., et al. (2006). Vaccine with beta-defensin 2-transduced leukemic cells activates innate and adaptive immunity to elicit potent antileukemia responses. Cancer Res. 66, 1169-1176.
38. Mapara, M. Y., and Sykes, M. (2004). Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J. Clin. Oncol. 22, 1136-1151.
39. Mei, H. F., Jin, X. B., Zhu, J. Y., et al. (2012). Beta-defensin 2 as an adjuvant promotes anti-melanoma immune responses and inhibits the growth of implanted murine melanoma in vivo. PLoS One 7, e31328.
40. Muller, C. A., Markovic-Lipkovski, J., Klatt, T., et al. (2002). Human alpha-defensins HNPs-1,-2, and-3 in renal cell carcinoma: influences on tumor cell proliferation. Am. J. Pathol. 160, 1311-1324.
41. Nair, S., McLaughlin, C., Weizer, A., et al. (2003). Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J. Immunol. 171, 6275-6282.
42. Ng-Cashin, J., Kuhns, J. J., Burkett, S. E., et al. (2003). Host absence of CCR5 potentiates dendritic cell vaccination. J. Immunol. 170, 4201-4208.
43. Nguyen, L. T., Atobe, K., Barichello, J. M., et al. (2007). Complex formation with plasmid DNA increases the cytotoxicity of cationic liposomes. Biol. Pharm. Bull. 30, 751-757.
44. Nicolas, A., Cathelin, D., Larmonier, N., et al. (2007). Dendritic cells trigger tumor cell death by a nitric oxide-dependent mechanism. J. Immunol. 179, 812-818.
45. Preynat-Seauve, O., Schuler, P., Contassot, E., et al. (2006). Tumor-infiltrating dendritic cells are potent antigen-presenting cells able to activate T cells and mediate tumor rejection. J. Immunol. 176, 61-67.
46. Roncarolo, M. G., Levings, M. K., and Traversari, C. (2001). Differentiation of T regulatory cells by immature dendritic cells. J. Exp. Med. 193, F5-F9.
47. Schutyser, E., Struyf, S., and Van Damme, J. (2003). The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev. 14, 409-426.
48. Shin, O., Kim, S. J., Lee, W. I., et al. (2008). Effective transduction by self-complementary adeno-associated viruses of human dendritic cells with no alteration of their natural characteristics. J. Gene Med. 10, 762-769.
49. Shortman, K., and Liu, Y. J. (2002). Mouse and human dendritic cell subtypes. Nat. Rev. Immunol. 2, 151-161.
50. Stary, G., Bangert, C., Tauber, M., et al. (2007). Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J. Exp. Med. 204, 1441-1451.
51. Taieb, J., Chaput, N., Menard, C., et al. (2006). A novel dendritic cell subset involved in tumor immunosurveillance. Nat. Med. 12, 214-219.
52. Wang, Y. S., Wang, G. Q., Wen, Y. J., et al. (2007). Immunity against tumor angiogenesis induced by a fusion vaccine with murine {beta}-defensin 2 and mFlk-1. Clin. Cancer Res. 13, 6779-6787.
53. Yang, D., Chertov, O., Bykovskaia, S. N., et al. (1999). Betadefensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 286, 525-528.
54. Yang, D., Chen, Q., Chertov, O., and Oppenheim, J. J. (2000). Human neutrophil defensins selectively chemoattract naive T and immature dendritic cells. J. Leukoc. Biol. 68, 9-14.